Therapeutic use of the retinoblastoma susceptibility gene product

This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the...

Full description

Saved in:
Bibliographic Details
Main Authors LEE; WEN-HWA, SHEPARD; H. MICHAEL, GOODRICH; DAVID W, JOHNSON; DUANE, WANG; NAN PING, LEE; EVA Y-H.P
Format Patent
LanguageEnglish
Published 22.12.1998
Edition6
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the cell with an effective amount of retinoblastoma protein or polypeptide. This method also is useful to prevent or treat retinoblastoma or a secondary cancer to retinoblastoma by administering to a patient a functional retinoblastoma protein or polypeptide.
AbstractList This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the cell with an effective amount of retinoblastoma protein or polypeptide. This method also is useful to prevent or treat retinoblastoma or a secondary cancer to retinoblastoma by administering to a patient a functional retinoblastoma protein or polypeptide.
Author LEE; WEN-HWA
JOHNSON; DUANE
GOODRICH; DAVID W
SHEPARD; H. MICHAEL
LEE; EVA Y-H.P
WANG; NAN PING
Author_xml – fullname: LEE; WEN-HWA
– fullname: SHEPARD; H. MICHAEL
– fullname: GOODRICH; DAVID W
– fullname: JOHNSON; DUANE
– fullname: WANG; NAN PING
– fullname: LEE; EVA Y-H.P
BookMark eNqFyjsOwjAQBUAXUPA7A3sBighFImWEQPSEOnLMS2LJeC3vuuD2UNBTTTNrs4gcsTJtNyPbhKLeUREQj6QzKEN95CFYUX5ZkiIOSf3gg9c3TYiglPlZnG7NcrRBsPu5MfvrpTvfDkjcQ5J136z9416f6qppqvb4f3wAqt0zng
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Edition 6
ExternalDocumentID US5851991A
GroupedDBID EVB
ID FETCH-epo_espacenet_US5851991A3
IEDL.DBID EVB
IngestDate Fri Jul 19 13:56:58 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US5851991A3
Notes Application Number: US19940306513
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19981222&DB=EPODOC&CC=US&NR=5851991A
ParticipantIDs epo_espacenet_US5851991A
PublicationCentury 1900
PublicationDate 19981222
PublicationDateYYYYMMDD 1998-12-22
PublicationDate_xml – month: 12
  year: 1998
  text: 19981222
  day: 22
PublicationDecade 1990
PublicationYear 1998
RelatedCompanies CANJI, INC
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
RelatedCompanies_xml – name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
– name: CANJI, INC
Score 2.4969816
Snippet This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title Therapeutic use of the retinoblastoma susceptibility gene product
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19981222&DB=EPODOC&locale=&CC=US&NR=5851991A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LT8MwDLbGQMANBmi8c0C9RfRJt0OFtj40Ie0h1qLdpqVNNQ60FW2F-Pc4YWVcdosSyUqiOP4S-7MBHoxebKV2wqnaT3RqrtSY9rhqUEsYJ64xpslgzPHkaRSZLwtr0YJ1w4WReUK_ZHJE1KgY9b2S93Wx_cTyZGxl-cjesSt_DkLHU5KGLqahvVO8oePPpt7UVVzXiebK5NUR3i-EQoM92BcgWmTZ99-GgpNS_DcowQkczFBWVp1Ci2cdOHKbumsdOBxv3N3Y3GheeQaDcEuUInXJSZ4SxG5EkBCznCEGrvKPFSnrUsapyJDXb4Kng5PiN6nrOdwHfuiOKM5l-bfsZTRvJm1cQDvLM94FsuJGjBCCGX2Vm8xM8bVlJppti0JSwl17Cd1dUq52D13DseTaaTrV9RtoV581v0VjW7E7uU8_xz2FPQ
link.rule.ids 230,309,786,891,25594,76903
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dT8IwEL8gGvFNUYOf9MHsbXGfDh4WAxsEFQaRzfC20K0EH9wWt8X433utTHzhrWmTy7Xp9e5697sDuNM7kbmyYiYr3ViTjaUSyR2m6LLJlRNTKVVFMubEexgFxvPCXNRgXWFhRJ3QL1EcESUqQnkvxHudbT-xXJFbmd_Td5xKH4e-7UpxBRdTUd9Jbt8ezKbu1JEcxw7mkvdq8-gXmkK9Pdi30CEUjtJbn2NSsv8KZXgMBzOklRQnUGNJExpO1XetCYeTTbgbhxvJy0-h52-BUqTMGUlXBG03wkGISUrRBi7SjyXJy1zkqYiU12-Ct4OR7Leo6xm0hwPfGcnIS_i37TCYV0zr51BP0oS1gCyZHqEJQfWuwgxqrNDbMmLVsngjKR6uvYDWLiqXu5fa0Bj5k3E4fvJeruBI4O5UTda0a6gXnyW7QcVb0FtxZj8mhogn
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Therapeutic+use+of+the+retinoblastoma+susceptibility+gene+product&rft.inventor=LEE%3B+WEN-HWA&rft.inventor=SHEPARD%3B+H.+MICHAEL&rft.inventor=GOODRICH%3B+DAVID+W&rft.inventor=JOHNSON%3B+DUANE&rft.inventor=WANG%3B+NAN+PING&rft.inventor=LEE%3B+EVA+Y-H.P&rft.date=1998-12-22&rft.externalDBID=A&rft.externalDocID=US5851991A